{"groups":[{"description":"Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment","id":"FG000","title":"Bevacizumab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was activated on 9/22/2008 and closed to accrual on 1/31/2011 (suspended from 1/4/2010 to 8/9/2010)."}